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Several components in the Wnt pathway, including β-catenin and glycogen synthase kinase 3 beta, have been implied in AD
pathogenesis. Here, mRNA brain levels from ﬁve-month-old tg-ArcSwe and nontransgenic mice were compared using Aﬀymetrix
microarray analysis. With surprisingly small overall changes, Wnt signaling was the most aﬀected pathway with altered expression
of nine genes in tg-ArcSwe mice. When analyzing mRNA levels of these genes in human brain, transcription factor 7-like 2
(TCF7L2) and v-myc myelocytomatosis viral oncogene homolog (MYC), were increased in Alzheimer’s disease (AD) (P<. 05).
Furthermore, no clear diﬀerences in TCF7L2 and MYC mRNA were found in brains with frontotemporal lobar degeneration,
suggesting that altered regulation of these Wnt-related genes could be speciﬁc to AD. Finally, mRNA levels of three neurogenesis
markers were analyzed. Increased mRNA levels of dihydropyrimidinase-like 3 were observed in AD brain, suggesting that altered
Wnt pathway regulation may signify synaptic rearrangement or neurogenesis.
1.Introduction
Alzheimer’s disease (AD) is the most common form of
dementia. The most prominent histopathological features of
the AD brain are extracellular plaques, mainly containing
amyloid-β (Aβ) peptides, and neuroﬁbrillary tangles largely
consisting of hyperphosphorylated tau. Studies on familial
casesofADhaveidentiﬁedseveraldisease-causingmutations
in the genes for the amyloid-β precursor protein (APP)
[1] and for the presenilins (PSEN1 and PSEN2)[ 2, 3].
In addition, the ε4 allele of the gene for apolipoprotein E
(APOE) lowers the age at onset of sporadic late-onset AD in
a dose-dependent manner [4, 5]. All these genetic variants
result in increased levels or in an altered aggregation of
Aβ, indicating a central role of Aβ in the disease process.
However, it is still unclear which downstream pathways that
are causing the synaptic dysfunction and cognitive failure
seen in AD.
Gene expression studies have found a wide range of
pathways that are altered in both human postmortem AD
brains and transgenic mouse models of AD. Examples
of such pathways include mitochondrial abnormalities,
oxidative stress, inﬂammation, and calcium dyshomeostasis
[6]. Moreover, the Wnt signaling pathway, consisting of a
complex network of proteins, has been implicated in AD
pathogenesis. For example, glycogen synthase kinase 3 beta
(GSK3β) hyperphosphorylates tau [7] and increases levels
of β-catenin in PSEN1 transgenic mice [8]. During Wnt2 International Journal of Alzheimer’s Disease
Table 1: Mouse samples studied.
Type n Age (weeks ±SEM) % female
Tg-ArcSwe 6 20.5±1.5 33
Nontransgenic 6 20.6±1.4 67
Tg-ArcSwe: transgenic mice, Nontransgenic: nontransgenic litter-
mates.
signaling, β-catenin translocates to the nucleus where it
forms complexes with transcription factor LEF/TCF (lym-
phoid enhancer factor/T-cellfactor) and activates target gene
expression. Finally, the Wnt pathway is also involved in cell
diﬀerentiation and cancer development [9].
Transgenic AD mice models have been of importance
to the understanding of disease mechanisms. One of these
models, the tg-ArcSwe mouse, overexpresses human APP
with the Swedish and the Arctic mutation. Studies on tg-
ArcSwemicesuggestthatintraneuronalAβaggregates,which
appear at one month and increase with age before the onset
of extracellular plaque deposition at six months [10, 11],
may be responsible for the spatial learning deﬁcits in these
mice [12]. This mouse model would thus be suitable to study
molecular changes related to early Aβ aggregation.
In this study we wanted to analyze and compare gene
expression patterns between young tg-ArcSwe and nontrans-
genic mice. In addition, we aimed at investigating whether
diﬀerentially expressed genes in this model also were altered
in brains from AD patients.
2.MaterialsandMethods
2.1. Samples. Six tg-ArcSwe and six nontransgenic mice
(littermates) were sacriﬁced by cervical dislocation. The
brain stem, cerebellum, and olfactory bulb were removed
by dissection, and the remaining hemispheres were frozen
separately on dry ice and stored at −80
◦C until processed.
All mice were approximately ﬁve months old and were of
the same genetic background, C57Bl/6J (Table 1). The use of
mice had been approved by the local ethical committee for
research on laboratory animals.
Human brain tissue from the anterior part of temporal
neocortex of 13 AD cases and nine age-matched controls
was obtained from the Alzheimer’s Disease Research Center
(ADRC) at Massachusetts General Hospital in Boston, USA
(Table 2). In addition, a separate set of tissues from the
anterior part of frontal neocortex from nine cases with
frontotemporal lobar degeneration (FTLD) and nine age-
matched controls, also from ADRC, were included (Table 2).
The tissues were stored at −80
◦C until processed. This
study was approved by the Regional Ethical Committees
in Uppsala, Sweden, and Massachusetts General Hospital,
Boston, USA.
2.2. RNA Extraction and cDNA Synthesis. Total RNA was
extracted from both mouse and human brain tissues. The
samples were homogenized in TRIzol (Invitrogen, Carlsbad,
CA, USA), and total RNA was extracted according to the
manufacturer’s protocol. The total RNA was further puriﬁed
using RNeasy Mini Kit (Qiagen, Valencia, CA, USA), fol-
lowing the manufacturer’s protocol. Total RNA quantity was
measured with NanoDrop ND-1000 UV-Vis Spectropho-
tometer (NanoDrop Technologies, Wilmington, DE, USA)
and RNA integrity through the 28S:18S rRNA ratio, as
measured by the Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Palo Alto, CA, USA). First-strand cDNA synthesis
w a sc a r r i e do u to n2μg total RNA with Superscript II ﬁrst-
strand synthesis kit for RT-PCR (Invitrogen), according to
the manufacturer’s protocol. Finally, 2.5ng of cDNA was
used for quantitative PCR (qPCR).
2.3.MicroarrayAnalyses. IndividualtotalRNAsamplesfrom
tg-ArcSwe and nontransgenic mice were hybridized to Af-
fymetrix GeneChip Mouse Genome 430 2.0 arrays (Affym-
etrix, Santa Clara, CA, USA). Robust multichip average
expression values were obtained from six arrays per group
a n df u r t h e ra n a l y z e df o rd i ﬀerential expression. Using the
Database for Annotation, Visualization and Integrated Dis-
covery (DAVID) [13], diﬀerentially expressed genes with a
P-value of less than .05 from the microarray analysis were
classiﬁed into diﬀerent molecular pathways according to the
Kyoto Encyclopedia of Genes and Genomes (KEGG) [14]
2.4. Quantitative PCR. Levels of mRNA from selected genes
were measured in mouse and human brain samples with
qPCR using the SYBR green chemistry on the MyiQ Single
Color Real Time PCR Detection System (Bio-Rad, Rich-
mond, CA, USA). The samples were prepared in a volume of
25μL, containing 2.5ng cDNA, 2x Power SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA, USA), and
200nM of each primer (sequences available upon request).
Next, the mixture was denatured in 95◦C (10min.), followed
by 40 cycles at 95◦C (15sec.) and 60◦C (1min.) before a ﬁnal
incubation at 95◦C (1min.). All primers were designed to
have an annealing temperature of 60
◦C.
All samples were run in triplicates, including a cali-
brator sample. Wells without template were included as
negative controls. Gene expression was determined relative
toGAPDH andnormalizedtothecalibratorsampleusingthe
2−ΔΔCt method (Applied Biosystems). Primers were designed
using Primer Express Software (Applied Biosystems) or
obtained from online Real Timer PCR Primer and Probe
Database [15]. Primers were evaluated in a qPCR eﬃciency
test on a dilution series of template. Unpaired t-tests with
Welch correction were performed using GraphPad InStat
(GraphPad Software, San Diego, CA, USA).
2.5. Western Blot on Human Brain Samples. For all subjects,
human brain tissue samples from the same region as
used for qPCR were homogenized in RIPA buﬀer (50mM
Tris (pH 8.0), 1% NP-40, 0.5% sodium deoxycholate, and
150mM NaCl, 0.1% SDS) supplemented with Complete
Protease Inhibitor Cocktail Tablet (Roche Applied Science,
Indianapolis, IN, USA), 1000μL per 50mg tissue. The
homogenate was incubated at 4◦C for two hours under
constant agitation. In the following, all incubation steps were
at room temperature.International Journal of Alzheimer’s Disease 3
Table 2: Human subjects studied.
Diagnosis Area n Age (years±SEM) PMI (hours±SEM) % female
AD Temporal ctx 13 79.8±1.5 14.8±1.5 46
C Temporal ctx 9 79.8±1.8 19.9±3.9 44
FTLD Frontal ctx 9 71.6±3.4 12.9±2.3 44
C Frontal ctx 9 82.4±2.6 19.3±4.2 56
PMI: postmortem interval, AD: Alzheimer’s disease, C: control subjects, and FTLD: frontotemporal lobar degeneration.
Forty μg of total protein from each homogenate was
mixed with sample buﬀer (1x Laemmli buﬀer, 0.1% bro-
mophenol blue, and 2.5% mercaptoethanol) and boiled (ﬁve
min.) before SDS-PAGE on a 10–20% Tris-Tricine gel (Bio-
Rad). Next, the proteins were transferred (over night) to
a nitrocellulose membrane (Bio-Rad) and blocked (1h.)
in TBS with 5% milk powder (BioRad). After washing in
TBS with 0.1% Tween (TBS-T), the samples were incubated
with primary antibody (1h.) and washed in TBS-T before
incubationwithﬂuorophore-conjugatedsecondaryantibody
(30min.). After washing in TBS-T and TBS, respectively,
ﬂuorescence was detected with the Odyssey imaging system
(LI-COR/Westburg, Leusden, Netherlands).
Inordertoadjustforunequalsampleloading,theprotein
levels were calculated as a ratio to GAPDH levels. Therefore,
after detection, the membranes were incubated with a
primary GAPDH antibody (30 min.). Next, they were
washed in TBS-T, followed by incubation with ﬂuorophore-
conjugated secondary antibody (30min.). After washing in
TBS-T and TBS, respectively, ﬂuorescence was measured
with the Odyssey.
Asprimaryantibodies,C-33(1:250,SantaCruzbiotech-
nology, Santa Cruz, CA, USA) was used for detection of
MYC, ab60727 (1:500, Abcam, Cambridge, MA, USA) and
6H5-3 (1:500, Upstate, Lake Placid, NY, USA) for TCF7L2
and G9545 (1:10000, Sigma-Aldrich, St. Louise, MO, USA)
for GAPDH. As secondary antibodies, IRdye 800CW-conju-
gated anti-mouse antibody (1:5000, Rockland, Gilbertsville,
PA,USA)wasusedforMYCandTCF7L2whereasAlexaﬂuor
680-conjugated anti-rabbit antibody (1:5000, VWR, West
Chester, PA, USA) was used for GAPDH. All antibodies were
diluted in 50/50 Odyssey buﬀer/TBS-T 0.2%.
2.6. Immunohistochemistry on Human Brains. Ten μmb r a i n
sections from tissue blocks embedded in paraﬃnf r o m
temporal cortex of ﬁve of the AD and four of the control
brains were included for immunohistochemistry. The tissues
were deparaﬃnized in xylene for ten minutes and incubated
in H2O2/methanol for 20 minutes followed by hydration
in decreasing concentrations of ethanol and H2O. Antigen
retrievalwasperformedincitratebuﬀer(20minutes,10mM,
pH 6.0, 95◦C). After a brief wash in PBS, the tissues were
blocked in normal goat serum (NGS, 5%) followed by incu-
bation overnight at 4◦C with the primary antibody in 1.5%
NGS (mouse anti-c-myc, 1:50, Santa Cruz Biotechnology;
anti-TCF7L2 1:500, Millipore, Billerica, MA). Next day,
the sections were washed in PBS followed by incubation
with the secondary antibody in 1.5% NGS (biotinylated
goat anti-mouse, 1:200). After additional washing in PBS,
the Vectastain Elite ABC kit (Vector Labs, Burlingame, CA)
and the DAB kit (Vector Labs) were used according to the
manufacturer’s instructions. Finally, sections were washed in
PBS and dehydrated in increasing concentrations of EtOH
and xylene before they were mounted with Permount.
3. Results
Altogether 530 genes were found to be diﬀerentially ex-
pressed (P<. 05) when comparing mRNA levels between
six tg-ArcSwe and six nontransgenic mice. The altered
genes were either down- or upregulated, ranging from 88%
to 112% of the reference levels in nontransgenic mice.
Using DAVID, the genes were categorized according to
their respective KEGG pathways. Thereby, three pathways
emerged as being particularly altered in the tg-ArcSwe mice:
the thyroid cancer pathway, the adipocytokine signaling
pathway, and the Wnt signaling pathway. Four of the genes
with altered expression were previously described to be
involved in thyroid cancer development, six of the genes in
adipocytokine signaling, and nine of the genes in the Wnt
signaling pathway. Of the Wnt-related genes, mRNA levels of
TCF7L2, CCND3, MYC, NKD2, and PPP3CB were increased
whereasmRNAlevelsofPLCB1,NFAT5,LEF1,andPPP2R2C
were decreased in transgenic as compared to nontransgenic
mice (Table 3).
As the Wnt signaling pathway demonstrated the highest
number of diﬀerentially expressed genes, we focused on
this pathway for further analyses. First, we wanted to
investigate whether the relatively small changes of the nine
Wnt pathway genes could be detected with an indepen-
dent technique. Therefore, we performed qPCR on cDNA
preparations derived from the same RNA samples that were
used for microarray analyses. However, after normalization
to GAPDH, the small changes between transgenic and
nontransgenic mice for the nine Wnt genes could not be
veriﬁed with this method (Table 3).
When examining mRNA levels of the nine Wnt signaling
pathway genes in human brains, two of the genes with
increased mRNA levels in transgenic brains, TCF7L2 and
MYC, displayed signiﬁcantly increased mRNA levels also in
AD brain (n = 13) as compared to nondemented control
brain (n = 9) (both P<. 05) (Table 3, Figure 1). Moreover,
the mRNA levels of these two genes were found to correlate
with each other in the AD samples (Spearman r = 0.896,
P<. 001) (Figure 1(c)). Unlike in transgenic mouse brains,
themRNAlevelsoftheotherseveninvestigatedgenesdidnot4 International Journal of Alzheimer’s Disease
Table 3: Fold changes and P values when comparing tg-ArcSwe mice and nontransgenic littermates and when comparing AD patients and
control subjects (C).
Gene Protein
Tg-ArcSwe versus nontransgenic AD versus C
Microarray qPCR qPCR
Fold change P Fold change P Fold change P
CCND3 Cyclin D3 1.10 <.05 0.88 n.s. 1.14 n.s.
LEF1 Lymphoid enhancer-binding factor 1 0.92 <.05 0.88 n.s. 0.90 n.s.
MYC V-myc myelocytomatosis viral oncogene homolog 1.09 <.05 0.91 n.s. 2.02 <.05
NFAT5 Nuclear factor of activated T-cells 5 0.91 <.05 0.96 n.s. 1.21 n.s.
NKD2 Naked cuticle homolog 2 (Drosophila) 1.08 <.05 1.05 n.s. 0.92 n.s.
PLCB1 Phospholipase C, beta 1 0.90 <.01 0.99 n.s. 0.82 n.s.
PPP2R2C Protein phosphatase 2, regulatory subunit B, gamma 0.93 <.05 1.21 n.s. 1.24 n.s.
PPP3CB Protein phosphatase 3, catalytic subunit 1.08 <.05 1.03 n.s. 0.79 n.s.

































Figure 1:RelativemRNAlevelsof(a)TCF7L2and(b)MYC incontrol(C)(n = 9)andAD(n = 13)brainasmeasuredbyqPCR,normalized
to GAPDH and to a calibrator sample (mean ± SEM, P<. 05 for both). (c) Correlation of TCF7L2 and MYC in the individual AD brains
(Spearman r = 0.9, P<. 0001).International Journal of Alzheimer’s Disease 5
s h o wa n ya l t e r e dl e v e l si nA Da sc o m p a r e dt ob r a i n sf r o m
healthy controls (Table 3).
In order to elucidate whether the observed alterations in
mRNA levels of TCF7L2 and MYC were AD-speciﬁc features
or a result of the neurodegenerative process itself, the two
genes were also analyzed in frontal neocortical tissue from
as e to fc a s e s( n = 9) with frontotemporal lobar degener-
ation (FTLD) and compared to frontal cortex tissue from
nondemented controls (n = 9). No signiﬁcant diﬀerences
were seen, although there was a trend for increased levels
of TCF7L2 mRNA in the FTLD group (P = .08) (data not
shown).
As the Wnt signaling pathway is known to be upreg-
ulated in neurogenesis, we wanted to explore whether
the increased mRNA levels of TCF7L2 and MYC reﬂected
neurogenesis in the AD brains. Thus, mRNA levels of two
neurogenesis markers (neural cell adhesion molecule 1—
NCAM1 [16] doublecortin—DCX [17]) and one marker for
neurons that are migrating or undergoing axonal growth
(dihydropyrimidinase-like 3—DPYSL3 [18]) were analyzed
by qPCR. Only mRNA levels of DPYSL3 were increased in
AD brain (P<. 05) whereas the NCAM1 and DCX mRNA
levels were unchanged as compared to control brains.
To investigate if the observed changes in mRNA levels
of TCF7L2 and MYC were paralleled by changes in the
corresponding proteins (transcription factor 7-like 2 and
v-myc myelocytomatosis viral oncogene homolog), western
blot and immunohistochemical analyses were carried out on
temporal neocortex from the same AD and control subjects.
For western blot, we used human brain tissue homogenates
from the same regions as that used for the mRNA analyses.
For transcription factor 7-like 2, no signals could be seen
in any of the brains using either of two antibodies. For v-
myc myelocytomatosis viral oncogene homolog, clear signals
were obtained but no signiﬁcant change was detected in
the AD cases (not shown). For immunohistochemistry on
temporal cortical sections, we obtained signals only from
transcription factor 7-like 2 but could not see any diﬀerences
between AD and control brains (not shown). For v-myc
myelocytomatosis viral oncogene homolog, no signals were
seen on immunohistochemistry from any of the tissues
investigated (not shown).
4. Discussion
The amyloid cascade hypothesis [19] is widely accepted, but
it is still unclear which form of Aβ that initiates the disease
process or has the most neurotoxic properties. Studies have
suggested that soluble Aβ oligomers are particularly toxic
[20]andeﬀectsongeneexpressionbysuchAβspeciesshould
therefore be of particular interest.
For this study, microarray analyses were performed on
ﬁve-month old tg-ArcSwe mice with marked accumulation
of intraneuronal Aβ and increased levels of soluble Aβ
protoﬁbrils in the brains [21]. For comparison, age-matched
nontransgenic littermates were used. The fold changes in
brainlevelsofvariousmRNAsfromthetransgenicmicewere
surprisingly small, ranging from 88% to 122% of that in
nontransgenic littermates. These subtle changes could have
been due to the fact that very young animals were used,
when Aβ possibly does not yet aﬀect biological pathways
to a great extent. The relatively small diﬀerences could also
have been explained by the fact that whole hemispheres
were used for extraction of RNA. If only areas displaying
intracellular Aβ had been used, the changes might have
been more pronounced. Nevertheless, the genes found to
be alternatively expressed in this microarray analysis may
represent downstream molecular cascades triggered by the
early formation of intracellular Aβ seen in this mouse model.
Three biochemical pathways—the thyroid cancer path-
way, the adipocytokine signaling pathway, and the Wnt
signaling pathway—were overrepresented among the genes
that had altered mRNA levels in the transgenic mice. Nine
genes from the Wnt pathway were found to be upregulated
in the mice brain. Although the fold changes were very small
and despite that we could not verify the increase for all nine
mRNA species by qPCR, we decided to further study the
Wnt pathway in postmortem AD brains. We then found that
two of the nine investigated genes, TCF7L2 and MYC,h a d
signiﬁcantly increased mRNA levels also in AD brain. Both
genes encode proteins that are part of the Wnt signaling
pathway, in which the transcription factor 7-like 2 regulates
transcription of the MYC gene [22]. This link in biological
activity was also well illustrated by the correlation between
the respective mRNA levels demonstrated in this study.
MYC is of particular interest as it has been illustrated
on a transgenic mouse model that induction of this proto-
oncogene can drive cell cycle re-entry and result in neuronal
cell death, gliosis, and cognitive deﬁcits [23]. Thus, the
upregulation of MYC mRNA in human brain could possibly
contribute to some of the neurodegenerative features seen in
AD.
T h eo b s e r v e di n c r e a s ei nm R N Al e v e l so fTCF7L2 and
MYC indicates an increase in Wnt signaling in AD patho-
genesis. Accordingly, recent evidence suggests that levels
of nuclear calcineurin are increased in post mortem AD
brains [24]. On the contrary, other studies have reported
increasedlevelsofGSK3β,suggestingarepressionoftheWnt
signaling pathway in AD [25]. However, in our study the
mRNA levels of both GSK3B and β-catenin were unchanged,
both in tg-ArcSwe mouse brain and in AD brain (data not
shown). In addition, the mRNA levels of PPP2R2C were
slightly decreased in tg-ArcSwe mouse brain whereas they
were nonsigniﬁcantly increased in the AD brain (Table 3).
T h eo b s e r v e di n c r e a s ei nm R N Al e v e l so fTCF7L2 and
MYC between AD and control brains was not paralleled
by increased levels of the respective proteins (transcription
factor 7-like 2 and v-myc myelocytomatosis viral oncogene
homolog). The discrepancy between mRNA and protein
levels may be explained by a rapid turnover in brain of these
signaling molecules.
Several lines of evidence suggest that both cell cycle acti-
vation and neurogenesis may be features in neurodegenera-
tion. In the AD brain, cell cycle re-entry is believed to occur
prior to the development of tangles and plaques (reviewed
in [26]). Moreover, Wnt signaling has been demonstrated to
betheprincipalregulatorofadulthippocampalneurogenesis
[27], which has been suggested to occur in the AD brain6 International Journal of Alzheimer’s Disease
[28]. We therefore reasoned that an upregulation of the
Wnt signaling pathway may be explained by an increased
neurogenesis in the investigated brains. One of the analyzed
genes known to be upregulated in neurogenesis indeed
displayed increased mRNA levels in our samples, suggesting
that an upregulated Wnt signaling pathway may be related
to increased neurogenesis in the AD brain. On the other
hand, mRNA levels of the two other neurogenesis-related
genes investigated were not found to be changed in AD, thus
making the interpretation more diﬃcult.
Interestingly, TCF7L2 was shown to be associated with
type II diabetes [29], and increased levels of TCF7L2 mRNA
in human islets have been found in type II diabetes [30].
There are commonalities between AD and diabetes with
bothdisordersbeingassociatedwithamyloidogenicdeposits,
and patients with diabetes have been reported to be more
prone to develop AD [31]. Also, soluble Aβ oligomers may
impair insulin signaling in the brain through a reduction in
neuronal surface insulin receptors [32]. Therefore, TCF7L2
may represent a molecular link between AD and diabetes
pathogenesis.
In conclusion, we have compared gene expression pat-
terns using microarray analysis of tg-ArcSwe and nontrans-
genic mice, indicating only subtle changes in mRNA levels in
young tg-ArcSwe. Interestingly, we found that the tg-ArcSwe
mice displayed altered mRNA levels of several members of
the Wnt signaling pathway as compared to nontransgenic
mice. Moreover, we have investigated whether diﬀerentially
expressed genes in this model also had altered mRNA levels
in brains from AD patients. The mRNA levels of two of these
genes, TCF7L2 and MYC, were signiﬁcantly increased also in
ADbrain(P<. 05),whereastheirlevelswerenotsigniﬁcantly
changed in frontal cortex of FTLD brains as compared to
frontal cortex from control brains. Although the number of
brains analyzed was limited, these results cautiously suggest
that the observed diﬀerences may be AD speciﬁc, rather than
a general feature of neurodegeneration. Finally, increased
mRNA levels of a neuronal plasticity marker suggest that the
upregulation of certain Wnt genes may give further support
for ongoing neurogenesis in the AD brain.
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